Tuesday, 13 March 2012

Piriton Syrup





1. Name Of The Medicinal Product



Piriton Syrup


2. Qualitative And Quantitative Composition



Each 5 ml of syrup contains 2mg of chlorphenamine maleate



3. Pharmaceutical Form



Syrup



Colourless syrup



4. Clinical Particulars



4.1 Therapeutic Indications



Piriton Syrup is indicated for symptomatic control of all allergic conditions responsive to antihistamines, including hay fever, vasomotor rhinitis, urticaria, angioneurotic oedema, food allergy, drug and serum reactions, insect bites.



Also indicated for the symptomatic relief of itch associated with chickenpox.



4.2 Posology And Method Of Administration



Oral administration only



Do not exceed the stated dose or frequency of dosing



Adults and children 12 years and over: 10ml (4mg) every 4 to 6 hourly. Maximum daily dose: 60ml (24mg) in any 24 hours.



Elderly: The elderly are more likely to experience neurological anticholinergic effects. Consideration should be given to using a lower daily dose (e.g. a maximum of 12 mg in any 24 hours).



Children aged 6 - 12 years: 5ml (2mg) every 4 to 6 hourly. Maximum daily dose: 30ml (12mg) in any 24 hours.



Children aged 2 - 6 years: 2.5ml (1mg) every 4 to 6 hourly. Maximum daily dose: 15ml (6mg) in any 24 hours.



Children aged 1 - 2 years: 2.5ml (1mg) twice daily. The minimum interval between the doses should be 4 hours. Maximum daily dose: 5ml (2mg) in any 24 hours.



Not recommended for children below 1 year



4.3 Contraindications



Piriton Syrup is contra-indicated in patients who are hypersensitive to antihistamines or to any of the syrup ingredients.



The anticholinergic properties of chlorphenamine are intensified by monoamine oxidase inhibitors (MAOIs). Piriton Syrup is therefore contra-indicated in patients who have been treated with MAOIs within the last fourteen days.



4.4 Special Warnings And Precautions For Use



Chlorphenamine, in common with other drugs having anticholinergic effects, should be used with caution in epilepsy; raised intra-ocular pressure including glaucoma; prostatic hypertrophy; severe hypertension or cardiovascular disease; bronchitis, bronchiectasis or asthma; hepatic impairment. Children and the elderly are more likely to experience the neurological anticholinergic effects and paradoxical excitation (eg. Increased energy, restlessness, nervousness).



The effects of alcohol may be increased and therefore concurrent use should be avoided.



Should not be used with other antihistamine containing products, including antihistamine containing cough and cold medicines.



Piriton syrup contains 6.3% v/v ethanol. Harmful for those suffering from alcoholism. To be taken into account in pregnant and breast feeding women, children and high risk groups such as patients with liver disease or epilepsy.



Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrose-isomaltase insufficiency should not take this medicine.



Piriton Syrup contains 2.36 g of sucrose per 5 ml. This should be taken into account in patients with diabetes mellitus.



Long term use increases the risk of dental caries and it is essential that adequate dental hygiene is maintained.



Methyl, ethyl and propyl hydroxybenzoates (E218, E214 and E216) may cause allergic reactions (possibly delayed).



Keep out of the reach and sight of children.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Concurrent use of chlorphenamine and hypnotics or anxiolytics may cause an increase in sedative effects, therefore medical advice should be sought before taking chlorphenamine concurrently with these medicines.



Chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity.



The anticholinergic effects of chlorphenamine are intensified by MAOIs (see Contra-indications).



4.6 Pregnancy And Lactation



Pregnancy



There are no adequate data from the use of chlorphenamine in pregnant women. The potential risk for humans is unknown, Use during the third trimester may result in reactions in the newborn or premature neonates. Not to be used during pregnancy unless considered essential by a physician.



Lactation



Chlorphenamine maleate and other antihistamines may inhibit lactation and may be secreted in breast milk. Not to be used during lactation unless considered essential by a physician.



4.7 Effects On Ability To Drive And Use Machines



The anticholinergic properties of chlorphenamine may cause drowsiness, dizziness, blurred vision and psychomotor impairment, which can seriously hamper the patients' ability to drive and use machinery.



4.8 Undesirable Effects



Specific estimation of the frequency of adverse events for OTC products is inherently difficult (particularly numerator data). Adverse reactions which have been observed in clinical trails and which are considered to be common (occurring in



Blood and lymphatic system disorders



Unknown: haemolytic anaemia, blood dyscrasias



Immune system disorders:



Unknown: allergic reaction, angioedema, anaphylactic reactions



Metabolism and nutritional disorders:



Unknown: anorexia



Psychiatric disorders:



Unknown: confusion*, excitation*, irritability*, nightmares*, depression



Nervous system disorders*:



Very common: sedation, somnolence



Common: disturbance in attention, abnormal coordination, dizziness, headache



Eye disorders:



Common: blurred vision



Ear and labyrinth disorders



Unknown: tinnitus



Cardiac disorders:



Unknown: palpitations, tachycardia, arrythmias



Vascular disorders:



Unknown: Hypotension



Respiratory, thoracic and Mediastinal disorders:



Unknown: thickening of bronchial secretions



Gastrointestinal disorders:



Common: nausea, dry mouth



Unknown: vomiting, abdominal pain, diarrhoea, dyspepsia



Hepatobiliary disorders:



Unknown: hepatitis including jaundice



Skin and subcutaneous disorders:



Unknown: exfoliative dermatitis, rash, urticaria, photosensitivity,



Musculoskeletal and connective tissue disorders:



Unknown: muscular twitching, muscle weakness.



Renal and Urinary disorders:



Unknown: Urinary retention



General disorders and administration site conditions:



Common: fatigue



Unknown: chest tightness



*Children and the elderly are more susceptible to neurological anticholinergic effects and paradoxical excitation (eg increased energy, restlessness, nervousness)



4.9 Overdose



Symptoms and signs



The estimated lethal dose of chlorphenamine is 25 to 50mg/kg body weight. Symptoms and signs include sedation, paradoxical excitation of the CNS, toxic psychosis, convulsions, apnoea, anticholinergic effects, dystonic reactions and cardiovascular collapse including arrhythmias.



Treatment



Symptomatic and supportive measures should be provided with special attention to cardiac, respiratory, renal and hepatic functions and fluid and electrolyte balance. If overdosage is by the oral route, treatment with activated charcoal should be considered provided there are no contraindications for use and the overdose has been taken recently (treatment is most effective if given within an hour of ingestion.) Treat hypotension and arrhythmias vigorously. CNS convulsions may be treated with i.v. diazepam. Haemoperfusion may be used in severe cases.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



ATC Code R06AB02



Chlorphenamine is a potent antihistamine (H1-antagonist).



Antihistamines diminish or abolish the actions of histamine in the body by competative reversible blockade of histamine H1-receptor sites on tissues. Chlorphenamine also has anticholinergic activity.



Antihistamines act to prevent the release of histamine, prostaglandins and leukotrines and have been shown to prevent the migration of inflammatory mediators. The actions of chlorphenmine include inhibition of histamine on smooth muscle, cappillary permeability and hence reduction of oedma and wheal in hypersneitivity reactions such as allergy and anaphylaxis.



5.2 Pharmacokinetic Properties



Chlorphenamine is well absorbed from the gastro-intestinal tract, following oral administration. The effects develop within 30 minutes, are maximal within 1 to 2 hours and last 4 to 6 hours. The plasma half-life has been estimated to be 12 to 15 hours.



Chlorphenamine is metabolised to the monodesmethyl and didesmethyl derivatives. About 22% of an oral dose is excreted unchanged in the urine.



5.3 Preclinical Safety Data



No additional data of relevance.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Syrup



Glycerol



Ethanol



Tingle flavour



Peppermint oil



Nipasept



Purified Water



6.2 Incompatibilities



None known



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



Store below 25ºC. Protect from light



6.5 Nature And Contents Of Container



Amber glass bottle containing 150ml Piriton Syrup. Supplied with a measuring spoon



or



Amber plastic bottle containing 150ml Piriton Syrup. Supplied with a measuring spoon



6.6 Special Precautions For Disposal And Other Handling



For detailed instructions for use refer to the Patient Information Leaflet in every pack.



Administrative Data


7. Marketing Authorisation Holder



Stafford Miller Limited



980 Great West Road



Brentford



Middlesex TW8 9GS



UNITED KINGDOM



Trading as: GlaxoSmithKline Consumer Healthcare, Brentford, TW8 9GS, UK.



8. Marketing Authorisation Number(S)



PL 00036/0088



9. Date Of First Authorisation/Renewal Of The Authorisation



14 February 1997/28 April 2000



10. Date Of Revision Of The Text



24/05/2010




Friday, 9 March 2012

amoxapine


a-MOX-a-peen


Oral route(Tablet)

Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies with major depressive disorder (MDD) and other psychiatric disorders. Short term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24, and there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. This risk must be balanced with the clinical need. Monitor patients closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Not approved for use in pediatric patients .



Commonly used brand name(s)

In the U.S.


  • Asendin

Available Dosage Forms:


  • Tablet

Therapeutic Class: Antidepressant


Pharmacologic Class: Antidepressant, Tricyclic


Chemical Class: Dibenzoxazepine


Uses For amoxapine


Amoxapine is used to treat the symptoms of depression. It works on the central nervous system (CNS) to increase levels of certain chemicals in the brain. amoxapine is a tricyclic antidepressant (TCA).


amoxapine is available only with your doctor's prescription.


Before Using amoxapine


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For amoxapine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to amoxapine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of amoxapine in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of amoxapine in the elderly. However, elderly patients are more likely to have unwanted effects (e.g., movement disorders, unusual drowsiness) or age-related kidney or liver problems, which may require an adjustment in the dose for patients receiving amoxapine.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking amoxapine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using amoxapine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Bepridil

  • Cisapride

  • Clorgyline

  • Dronedarone

  • Grepafloxacin

  • Isocarboxazid

  • Levomethadyl

  • Linezolid

  • Mesoridazine

  • Methylene Blue

  • Metoclopramide

  • Moclobemide

  • Phenelzine

  • Pimozide

  • Ranolazine

  • Selegiline

  • Sparfloxacin

  • Terfenadine

  • Thioridazine

  • Tranylcypromine

Using amoxapine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Acecainide

  • Alfuzosin

  • Amiodarone

  • Amisulpride

  • Amitriptyline

  • Amprenavir

  • Apomorphine

  • Aprindine

  • Arsenic Trioxide

  • Asenapine

  • Astemizole

  • Azimilide

  • Azithromycin

  • Bretylium

  • Chloral Hydrate

  • Chloroquine

  • Chlorpromazine

  • Ciprofloxacin

  • Citalopram

  • Clarithromycin

  • Clomipramine

  • Clonidine

  • Clozapine

  • Crizotinib

  • Dasatinib

  • Desipramine

  • Dextromethorphan

  • Disopyramide

  • Dofetilide

  • Dolasetron

  • Droperidol

  • Enflurane

  • Epinephrine

  • Erythromycin

  • Etilefrine

  • Flecainide

  • Fluconazole

  • Fluoxetine

  • Foscarnet

  • Gatifloxacin

  • Gemifloxacin

  • Granisetron

  • Halofantrine

  • Haloperidol

  • Halothane

  • Ibutilide

  • Iloperidone

  • Imipramine

  • Indacaterol

  • Iproniazid

  • Isoflurane

  • Isradipine

  • Lapatinib

  • Levofloxacin

  • Lidoflazine

  • Lopinavir

  • Lorcainide

  • Lumefantrine

  • Mefloquine

  • Methadone

  • Methoxamine

  • Midodrine

  • Moricizine

  • Moxifloxacin

  • Nefopam

  • Nialamide

  • Nilotinib

  • Norepinephrine

  • Norfloxacin

  • Nortriptyline

  • Octreotide

  • Ofloxacin

  • Ondansetron

  • Oxilofrine

  • Paliperidone

  • Pargyline

  • Pazopanib

  • Pentamidine

  • Perflutren Lipid Microsphere

  • Phenylephrine

  • Posaconazole

  • Procainamide

  • Procarbazine

  • Prochlorperazine

  • Promethazine

  • Propafenone

  • Protriptyline

  • Quetiapine

  • Quinidine

  • Quinine

  • Rasagiline

  • Risperidone

  • Saquinavir

  • Sematilide

  • Sertindole

  • Sertraline

  • Sodium Phosphate

  • Sodium Phosphate, Dibasic

  • Sodium Phosphate, Monobasic

  • Solifenacin

  • Sorafenib

  • Sotalol

  • Spiramycin

  • Sulfamethoxazole

  • Sultopride

  • Sunitinib

  • Tapentadol

  • Tedisamil

  • Telavancin

  • Telithromycin

  • Tetrabenazine

  • Toloxatone

  • Toremifene

  • Tramadol

  • Trazodone

  • Trifluoperazine

  • Trimethoprim

  • Trimipramine

  • Vandetanib

  • Vardenafil

  • Vasopressin

  • Vemurafenib

  • Venlafaxine

  • Voriconazole

  • Ziprasidone

  • Zolmitriptan

  • Zotepine

Using amoxapine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Acenocoumarol

  • Arbutamine

  • Atomoxetine

  • Cannabis

  • Carbamazepine

  • Dicumarol

  • Paroxetine

  • Phenprocoumon

  • S-Adenosylmethionine

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using amoxapine with any of the following may cause an increased risk of certain side effects but may be unavoidable in some cases. If used together, your doctor may change the dose or how often you use amoxapine, or give you special instructions about the use of food, alcohol, or tobacco.


  • Ethanol

Other Medical Problems


The presence of other medical problems may affect the use of amoxapine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Bipolar disorder (mood disorder with alternating episodes of mania and depression), or risk of or

  • Heart attack, recent—Should not be used in patients with these conditions.

  • Glaucoma, history of or

  • Heart disease or

  • Schizophrenia or

  • Seizures, history of or

  • Urinary retention (trouble urinating), history of—Use with caution. May make these conditions worse.

Proper Use of amoxapine


Take amoxapine only as directed by your doctor to benefit your condition as much as possible. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.


amoxapine should come with a medication guide. Read and follow these instructions carefully. Ask your doctor if you have any questions.


Dosing


The dose of amoxapine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of amoxapine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage form (tablets):
    • For depression:
      • Adults—At first, 50 milligrams (mg) two or three times per day. Your doctor may increase your dose as needed. However, the dose is usually not more than 300 mg per day unless you are in a hospital. Some hospitalized patients may need higher doses. If you are taking amoxapine once a day, it is best to take it at bedtime.

      • Older Adults—At first, 25 milligrams (mg) two or three times per day. Your doctor may increase your dose as needed. However, the dose is usually not more than 300 mg per day unless you are in a hospital. Some hospitalized patients may need higher doses. If you are taking amoxapine once a day, it is best to take it at bedtime.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of amoxapine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using amoxapine


It is very important that your doctor check your progress at regular visits to allow for changes in your dose and to check for any unwanted effects.


Amoxapine may cause some people to be agitated, irritable, or display other abnormal behaviors. It may also cause some people to have suicidal thoughts and tendencies or to become more depressed. If you, your child, or your caregiver notice any of these side effects, tell your doctor or your child's doctor right away.


Do not take amoxapine if you have taken a monoamine oxidase (MAO) inhibitor (isocarboxazid [Marplan®], phenelzine [Nardil®], selegiline [Eldepryl®, or tranylcypromine [Parnate®]) in the past two weeks. Do not start taking a MAO inhibitor within two weeks of stopping amoxapine. If you do, you may develop confusion, agitation, restlessness, stomach or intestinal symptoms, sudden high body temperature, extremely high blood pressure, or severe convulsions.


amoxapine may cause tardive dyskinesia (a movement disorder). Check with your doctor right away if you have any of the following symptoms while taking amoxapine: lip smacking or puckering, puffing of the cheeks, rapid or worm-like movements of the tongue, uncontrolled chewing movements, or uncontrolled movements of the arms and legs.


Check with your doctor right away if you are having convulsions (seizures); difficulty with breathing; a fast heartbeat; high fever; high or low blood pressure; increased sweating; loss of bladder control; severe muscle stiffness; unusually pale skin; or tiredness. These could be symptoms of a serious condition called neuroleptic malignant syndrome (NMS).


Do not stop taking amoxapine without first checking with your doctor . Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help prevent a possible worsening of your condition and reduce the possibility of withdrawal symptoms such as headache, nausea, or a general feeling of discomfort or illness.


amoxapine will add to the effects of alcohol and other central nervous system (CNS) depressants (medicines that cause drowsiness). Some examples of CNS depressants are antihistamines or medicine for hay fever, other allergies or colds; sedatives, tranquilizers, or sleeping medicines; prescription pain medicine or narcotics; barbiturates; medicine for seizures; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are using amoxapine.


amoxapine may cause some people to become drowsy or less alert than they are normally. Make sure you know how you react to amoxapine before you drive, use machines, or do anything else that could be dangerous if you are drowsy or not alert.


amoxapine Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Less common
  • Excitement

  • fast, irregular, pounding, or racing heartbeat or pulse

  • fear or nervousness

  • mood or mental changes

  • nightmares

  • restlessness

  • shakiness and unsteady walk

  • shakiness in legs, arms, hands, or feet

  • sleeplessness

  • swelling

  • trouble sleeping

  • unable to sleep

  • unsteadiness, trembling, or other problems with muscle control or coordination

Rare
  • Abdominal or stomach pain

  • actions that are out of control

  • black, tarry stools

  • bleeding gums

  • bloating

  • blood in urine or stools

  • blurred vision

  • burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings

  • chest pain or discomfort

  • chills

  • clay-colored stools

  • confusion

  • confusion about identity, place, and time

  • constipation

  • continuing ringing or buzzing or other unexplained noise in ears

  • convulsions

  • cough or hoarseness

  • dark urine

  • decrease in frequency of urination

  • decrease in urine volume

  • difficulty in breathing

  • difficulty in passing urine (dribbling)

  • difficulty in speaking

  • disturbed concentration

  • dizziness, faintness, or lightheadedness when getting up from a lying or sitting position suddenly

  • double vision

  • drooling

  • extremely high fever or body temperature

  • false beliefs that cannot be changed by facts

  • fast, weak heartbeat

  • fever with or without chills

  • general feeling of tiredness or weakness

  • headache

  • hearing loss

  • high fever

  • high or low blood pressure

  • hives or welts

  • inability to move arms, legs, or facial muscles

  • inability to speak

  • increased need to urinate

  • increased sweating

  • indigestion

  • irritability

  • itching

  • lack of coordination

  • light-colored stools

  • lip smacking or puckering

  • loss of appetite

  • loss of bladder control

  • lower back or side pain

  • muscle cramps

  • muscle spasm or jerking of all extremities

  • muscle trembling, jerking, or stiffness

  • nausea and vomiting

  • nervousness

  • numbness

  • pain or discomfort in arms, jaw, back, or neck

  • painful or difficult urination

  • pains in stomach, side, or abdomen, possibly radiating to the back

  • pale, clammy skin

  • passing urine more often

  • pinpoint red spots on skin

  • pounding in the ears

  • puffing of cheeks

  • rapid or worm-like movements of tongue

  • redness of skin

  • seeing, hearing, or feeling things that are not there

  • severe muscle stiffness

  • shortness of breath

  • shuffling walk

  • skin rash

  • slow speech

  • sore throat

  • sores, ulcers, or white spots on lips or in mouth

  • stiffness of limbs

  • sudden loss of consciousness

  • sweating

  • swollen glands

  • talking, feeling, and acting with excitement

  • testicular swelling

  • thirst

  • trouble in holding or releasing urine

  • twisting movements of body

  • uncontrolled chewing movements

  • uncontrolled movements, especially of face, neck, and back

  • unpleasant breath odor

  • unusual bleeding or bruising

  • unusually pale skin

  • upper right abdominal pain

  • vomiting of blood

  • yellow eyes and skin

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Change in consciousness

  • drowsiness

  • epileptic seizure that will not stop

  • fatigue

  • increased blood pressure

  • increased thirst

  • loss of consciousness

  • swelling of face, fingers, or lower legs

  • total body jerking

  • troubled breathing

  • weight gain

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Dry mouth

Less common
  • Increased appetite

  • increased flow of breast milk

Rare
  • Agitation

  • breast enlargement

  • change in taste bad unusual or unpleasant (after)taste

  • decreased interest in sexual intercourse

  • depression

  • excess air or gas in stomach or intestines

  • full feeling

  • hair loss, thinning of hair

  • heartburn

  • inability to have or keep an erection

  • increased in sexual ability, desire, drive, or performance

  • increased interest in sexual intercourse

  • increased sensitivity of skin to sunlight

  • loss in sexual ability, desire, drive, or performance

  • menstrual changes

  • nasal stuffiness

  • painful ejaculation

  • passing gas

  • rapid weight gain

  • redness or other discoloration of skin

  • seizures

  • severe sunburn

  • stupor

  • swollen, painful, or tender lymph glands on side of face or neck

  • tearing of the eyes

  • unexpected or excess milk flow from breasts

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: amoxapine side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More amoxapine resources


  • Amoxapine Side Effects (in more detail)
  • Amoxapine Dosage
  • Amoxapine Use in Pregnancy & Breastfeeding
  • Drug Images
  • Amoxapine Drug Interactions
  • Amoxapine Support Group
  • 2 Reviews for Amoxapine - Add your own review/rating


  • amoxapine Concise Consumer Information (Cerner Multum)

  • Amoxapine Prescribing Information (FDA)

  • Amoxapine Professional Patient Advice (Wolters Kluwer)

  • Amoxapine MedFacts Consumer Leaflet (Wolters Kluwer)

  • Amoxapine Monograph (AHFS DI)



Compare amoxapine with other medications


  • Depression

Azasan





Dosage Form: tablet
Azasan® (azathioprine)

Azathioprine Tablets, USP

75 mg Scored Tablets

100 mg Scored Tablets


WARNING - MALIGNANCY Chronic immunosuppression with this purine antimetabolite increases risk of malignancy in humans. Reports of malignancy include post-transplant lymphoma and hepatosplenic T-cell lymphoma (HSTCL) in patients with inflammatory bowel disease. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. Physicians should inform patients of the risk of malignancy with Azasan. See WARNINGS.




DESCRIPTION:


Azasan®, an immunosuppressive antimetabolite, is available in tablet form for oral administration. Each scored tablet contains 75 mg or 100 mg azathioprine and the inactive ingredients lactose monohydrate, pregelatinized starch, povidone, corn starch, magnesium stearate, and stearic acid.


Azathioprine is chemically 1H-purine, 6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]. The structural formula of azathioprine is:



It is an imidazolyl derivative of 6-mercaptopurine and many of its biological effects are similar to those of the parent compound.


Azathioprine is insoluble in water, but may be dissolved with addition of one molar equivalent of alkali. Azathioprine is stable in solution at neutral or acid pH but hydrolysis to mercaptopurine occurs in excess sodium hydroxide (0.1N), especially on warming. Conversion to mercaptopurine also occurs in the presence of sulfhydryl compounds such as cysteine, glutathione, and hydrogen sulfide.



CLINICAL PHARMACOLOGY:


Azathioprine is well absorbed following oral administration. Maximum serum radioactivity occurs at 1 to 2 hours after oral 35S-azathioprine and decays with a half-life of 5 hours. This is not an estimate of the half-life of azathioprine itself, but is the decay rate for all 35S-containing metabolites of the drug. Because of extensive metabolism, only a fraction of the radioactivity is present as azathioprine. Usual doses produce blood levels of azathioprine, and of mercaptopurine derived from it, which are low (<1 mcg/mL). Blood levels are of little predictive value for therapy since the magnitude and duration of clinical effects correlate with thiopurine nucleotide levels in tissues rather than with plasma drug levels. Azathioprine and mercaptopurine are moderately bound to serum proteins (30%) and are partially dialyzable. See OVERDOSAGE.


Azathioprine is metabolized to 6-mercaptopurine (6-MP). Both compounds are rapidly eliminated from blood and are oxidized or methylated in erythrocytes and liver; no azathioprine or mercaptopurine is detectable in urine after 8 hours. Activation of 6-mercaptopurine occurs via hypoxanthine-guanine phosphoribosyltransferase (HGPRT) and a series of multi-enzymatic processes involving kinases to form 6-thioguanine nucleotides (6-TGNs) as major metabolites (See Metabolism Scheme in Figure 1). The cytotoxicity of azathioprine is due, in part, to the incorporation of 6-TGN into DNA.


6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. TPMT activity correlates inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway. Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of Azasan. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of Azasan.4-9 TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing Azasan toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. See WARNINGS, PRECAUTIONS: Drug Interactions, PRECAUTIONS: Laboratory Tests and ADVERSE REACTIONS sections.



Figure 1. Metabolism pathway of azathioprine: competing pathways result in inactivation by TPMT or XO, or incorporation of cytotoxic nucleotides into DNA.


GMPS: Guanosine monophosphate synthetase; HGPRT: Hypoxanthine-guanine-phosphoribosyl-transferase; IMPD: Inosine monophosphate dehydrogenase; MeMP: Methylmercaptopurine; MeMPN: Methylmercaptopurine nucleotide; TGN: Thioguanine nucleotides; TIMP: Thioinosine monophosphate; TPMT: Thiopurine S-methyltransferase; TU Thiouric acid; XO: Xanthine oxidase (Adapted from Pharmacogenomics 2002; 3:89-98; and Cancer Res 2001; 61:5810-5816.)


Another inactivation pathway is oxidation, which is catalyzed by xanthine oxidase (XO) to form 6-thiouric acid. The inhibition of xanthine oxidase in patients receiving allopurinol is the basis for the azathioprine dosage reduction required in these patients (see PRECAUTIONS: Drug Interactions).


Proportions of metabolites are different in individual patients, and this presumably accounts for variable magnitude and duration of drug effects. Renal clearance is probably not important in predicting biological effectiveness or toxicities, although dose reduction is practiced in patients with poor renal function.



Homograft Survival:


The use of azathioprine for inhibition of renal homograft rejection is well established, the mechanism(s) for this action are somewhat obscure. The drug suppresses hypersensitivities of the cell-mediated type and causes variable alterations in antibody production. Suppression of T-cell effects, including ablation of T-cell suppression, is dependent on the temporal relationship to antigenic stimulus or engraftment. This agent has little effect on established graft rejections or secondary responses.


Alterations in specific immune responses or immunologic functions in transplant recipients are difficult to relate specifically to immunosuppression by azathioprine. These patients have subnormal responses to vaccines, low numbers of T-cells, and abnormal phagocytosis by peripheral blood cells, but their mitogenic responses, serum immunoglobulins, and secondary antibody responses are usually normal.



Immunoinflammatory Response:


Azathioprine suppresses disease manifestations as well as underlying pathology in animal models of autoimmune disease. For example, the severity of adjuvant arthritis is reduced by azathioprine.


The mechanisms whereby azathioprine affects autoimmune diseases are not known. Azathioprine is immunosuppressive, delayed hypersensitivity and cellular cytotoxicity tests being suppressed to a greater degree than are antibody responses. In the rat model of adjuvant arthritis, azathioprine has been shown to inhibit the lymph node hyperplasia, which precedes the onset of the signs of the disease. Both the immunosuppressive and therapeutic effects in animal models are dose-related. Azathioprine is considered a slow-acting drug and effects may persist after the drug has been discontinued.



INDICATIONS AND USAGE:


Azasan is indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms.



Renal Homotransplantation:


Azasan is indicated as an adjunct for the prevention of rejection in renal homotransplantation. Experience with over 16,000 transplants shows a 5-year patient survival of 35% to 55%, but this is dependent on donor, match for HLA antigens, anti-donor or anti-B-cell alloantigen antibody, and other variables. The effect of azathioprine on these variables has not been tested in controlled trials.



Rheumatoid Arthritis:


Azasan is indicated for the treatment of active rheumatoid arthritis (RA) to reduce signs and symptoms. Aspirin, non-steroidal anti-inflammatory drugs and/or low dose glucocorticoids may be continued during treatment with Azasan. The combined use of azathioprine with disease modifying anti-rheumatic drugs (DMARDs) has not been studied for either added benefit or unexpected adverse effects. The use of Azasan with these agents cannot be recommended.



CONTRAINDICATIONS:


Azasan should not be given to patients who have shown hypersensitivity to the drug.


Azasan should not be used for treating rheumatoid arthritis in pregnant women.


Patients with rheumatoid arthritis previously treated with alkylating agents (cyclophosphamide, chlorambucil, melphalan, or others) may have a prohibitive risk of malignancy if treated with Azasan.



WARNINGS:



Malignancy


Patients receiving immunosuppressants, including Azasan, are at increased risk of developing lymphoma and other malignancies, particularly of the skin. Physicians should inform patients of the risk of malignancy with Azasan. As usual for patients with increased risk for skin cancer, exposure to sunlight and ultraviolet light should be limited by wearing protective clothing and using a sunscreen with a high protection factor.


Post-transplant:

Renal transplant patients are known to have an increased risk of malignancy, predominantly skin cancer and reticulum cell or lymphomatous tumors. The risk of post-transplant lymphomas may be increased in patients who receive aggressive treatment with immunosuppressive drugs, including Azasan. Therefore, immunosuppressive drug therapy should be maintained at the lowest effective levels.


Rheumatoid Arthritis:

Information is available on the risk of malignancy with the use of azathioprine in rheumatoid arthritis (see ADVERSE REACTIONS). It has not been possible to define the precise risk of malignancy due to azathioprine. The data suggest the risk may be elevated in patients with rheumatoid arthritis, though lower than for renal transplant patients. However, acute myelogenous leukemia as well as solid tumors have been reported in patients with rheumatoid arthritis who have received azathioprine.


Inflammatory Bowel Disease:

Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with azathioprine. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn's disease or ulcerative colitis and the majority were in adolescent and young adult males. Some of the patients were treated with azathioprine as monotherapy and some had received concomitant treatment with a TNFα blocker at or prior to diagnosis. The safety and efficacy of Azasan for the treatment of Crohn's disease and ulcerative colitis have not been established.


Cytopenias:

Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with Azasan. Severe bone marrow suppression may also occur. Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of Azasan. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of Azasan. TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing Azasan toxicity.2-9 See PRECAUTIONS: Laboratory Tests. Hematologic toxicities are dose-related and may be more severe in renal transplant patients whose homograft is undergoing rejection. It is suggested that patients on Azasan have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary. Delayed hematologic suppression may occur. Prompt reduction in dosage or temporary withdrawal of the drug may be necessary if there is a rapid fall in or persistently low leukocyte count, or other evidence of bone marrow depression. Leukopenia does not correlate with therapeutic effect; therefore the dose should not be increased intentionally to lower the white blood cell count.



Serious Infections:


Serious infections are a constant hazard for patients receiving chronic immunosuppression, especially for homograft recipients. Fungal, viral, bacterial, and protozoal infections may be fatal and should be treated vigorously. Reduction of azathioprine dosage and/or use of other drugs should be considered.



Effect on Sperm in Animals:


Azathioprine has been reported to cause temporary depression in spermatogenesis and reduction in sperm viability and sperm count in mice at doses 10 times the human therapeutic dose;10 a reduced percentage of fertile matings occurred when animals received 5 mg/kg.11



Pregnancy: Pregnancy Category D


Azasan can cause fetal harm when administered to a pregnant woman. Azasan should not be given during pregnancy without careful weighing of risk versus benefit. Whenever possible, use of Azasan in pregnant patients should be avoided. This drug should not be used for treating rheumatoid arthritis in pregnant women.12


Azasan is teratogenic in rabbits and mice when given in doses equivalent to the human dose (5 mg/kg daily). Abnormalities included skeletal malformations and visceral anomalies.11


Limited immunologic and other abnormalities have occurred in a few infants born of renal allograft recipients on Azasan. In a detailed case report,13 documented lymphopenia, diminished IgG and IgM levels, CMV infection, and a decreased thymic shadow were noted in an infant born to a mother receiving 150 mg azathioprine and 30 mg prednisone daily throughout pregnancy. At 10 weeks most features were normalized. DeWitte et al reported pancytopenia and severe immune deficiency in a preterm infant whose mother received 125 mg azathioprine and 12.5 mg prednisone daily.14 There have been two published reports of abnormal physical findings. Williamson and Karp described an infant born with preaxial polydactyly whose mother received azathioprine 200 mg daily and prednisone 20 mg every other day during pregnancy.15 Tallent et al described an infant with a large myelomeningocele in the upper lumbar region, bilateral dislocated hips, and bilateral talipes equinovarus. The father was on long-term azathioprine therapy.16


Benefit versus risk must be weighed carefully before use of Azasan in patients of reproductive potential. There are no adequate and well-controlled studies in pregnant women. If this drug is used during pregnancy or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing age should be advised to avoid becoming pregnant.



PRECAUTIONS:



General:


A gastrointestinal hypersensitivity reaction characterized by severe nausea and vomiting has been reported. These symptoms may also be accompanied by diarrhea, rash, fever, malaise, myalgias, elevations in liver enzymes, and occasionally, hypotension. Symptoms of gastrointestinal toxicity most often develop within the first several weeks of therapy with Azasan and are reversible upon discontinuation of the drug. The reaction can recur within hours after re-challenge with a single dose of Azasan.



Information for Patients:


Patients being started on Azasan should be informed of the necessity of periodic blood counts while they are receiving the drug and should be encouraged to report any unusual bleeding or bruising to their physician. They should be informed of the danger of infection while receiving Azasan and asked to report signs and symptoms of infection to their physician. Careful dosage instructions should be given to the patient, especially when Azasan is being administered in the presence of impaired renal function or concomitantly with allopurinol (see Drug Interactions subsection and DOSAGE AND ADMINISTRATION). Patients should be advised of the potential risks of the use of Azasan during pregnancy and during the nursing period. The increased risk of malignancy following therapy with Azasan should be explained to the patient.



Laboratory Tests: Complete Blood Count (CBC) Monitoring:


Patients on Azasan should have complete blood counts, including platelet counts, weekly during the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage alterations or other therapy changes are necessary.


TPMT Testing: It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING Azasan. See CLINICAL PHARMACOLOGY, WARNINGS, ADVERSE REACTIONS and DOSAGE AND ADMINISTRATION sections.



Drug Interactions: Use with Allopurinol: One of the pathways for inactivation of azathioprine is inhibited by allopurinol. Patients receiving Azasan and allopurinol concomitantly should have a dose reduction of Azasan, to approximately 1/3 to 1/4 the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving Azasan and allopurinol because both TPMT and XO inactivation pathways are affected. See CLINICAL PHARMACOLOGY, WARNINGS, PRECAUTIONS:Laboratory Tests and ADVERSE REACTIONS sections.


Use with Aminosalicylates: There is in vitro evidence that aminosalicylate derivatives (e.g., sulphasalazine, mesalazine, or olsalazine) inhibit the TPMT enzyme. Concomitant use of these agents with Azasan should be done with caution.


Use with Other Agents Affecting Myelopoesis: Drugs which may affect leukocyte production, including co-trimoxazole, may lead to exaggerated leukopenia, especially in renal transplant recipients.


Use with Angiotensin-Converting Enzyme Inhibitors: The use of angiotensin-converting enzyme inhibitors to control hypertension in patients on azathioprine has been reported to induce anemia and severe leukopenia.


Use with Warfarin: Azasan may inhibit the anticoagulant effect of warfarin.


Use with ribavirin: The use of ribavirin for hepatitis C in patients receiving azathioprine has been reported to induce severe pancytopenia and may increase the risk of azathioprine-related myelotoxicity. Inosine monophosphate dehydrogenase (IMDH) is required for one of the metabolic pathways of azathioprine. Ribavirin is known to inhibit IMDH, thereby leading to accumulation of an azathioprine metabolite, 6-methylthioionosine monophosphate (6-MTITP), which is associated with myelotoxicity (neutropenia, thrombocytopenia, and anemia). Patients receiving azathioprine with ribavirin should have complete blood counts, including platelet counts, monitored weekly for the first month, twice monthly for the second and third months of treatment, then monthly or more frequently if dosage or other therapy changes are necessary.



Carcinogenesis, Mutagenesis, Impairment of Fertility: See WARNINGS section.



Pregnancy: Teratogenic Effects: Pregnancy Category D. See WARNINGS section.



Nursing Mothers: The use of Azasan in nursing mothers is not recommended. Azathioprine or its metabolites are transferred at low levels, both transplacentally and in breast milk. 17, 18, 19 Because of the potential for tumorigenicity shown for azathioprine, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use: Safety and efficacy of azathioprine in pediatric patients have not been established.



ADVERSE REACTIONS:


The principal and potentially serious toxic effects of Azasan are hematologic and gastrointestinal. The risks of secondary infection and malignancy are also significant (see WARNINGS). The frequency and severity of adverse reactions depend on the dose and duration of Azasan as well as on the patient's underlying disease or concomitant therapies. The incidence of hematologic toxicities and neoplasia encountered in groups of renal homograft recipients is significantly higher than that in studies employing Azasan for rheumatoid arthritis. The relative incidences in clinical studies are summarized below:
























 

* Data on the rate and risk of neoplasia among persons with rheumatoid arthritis treated with azathioprine are limited. The incidence of lymphoproliferative disease in patients with RA appears to be significantly higher than that in the general population. In one completed study, the rate of lymphoproliferative disease in RA patients receiving higher than recommended doses of azathioprine (5 mg/kg per day) was 1.8 cases per 1000 patient-years of follow-up, compared with 0.8 cases per 1000 patient-years of follow-up in those not receiving azathioprine. However, the proportion of the increased risk attributable to the azathioprine dosage or to other therapies (i.e., alkylating agents) received by patients treated with azathioprine cannot be determined.


 Toxicity Renal Homograft Rheumatoid Arthritis
 Leukopenia (any degree) >50% 28%
  <2500 cells/mm3 16% 5.3%
  Infections 20% <1%
 Neoplasia        *
  Lymphoma 0.5% 
  Others 2.8% 

Hematologic: Leukopenia and/or thrombocytopenia are dose-dependent and may occur late in the course of therapy with Azasan. Dose reduction or temporary withdrawal may result in reversal of these toxicities. Infection may occur as a secondary manifestation of bone marrow suppression or leukopenia, but the incidence of infection in renal homotransplantation is 30 to 60 times that in rheumatoid arthritis. Anemias, including macrocytic anemia, and/or bleeding have been reported.


TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from Azasan. See CLINICAL PHARMACOLOGY, WARNINGS and PRECAUTIONS:Laboratory Tests. Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine. 6, 20



Gastrointestinal: Nausea and vomiting may occur within the first few months of therapy with Azasan, and occurred in approximately 12% of 676 rheumatoid arthritis patients. The frequency of gastric disturbance often can be reduced by administration of the drug in divided doses and/or after meals. However, in some patients, nausea and vomiting may be severe and may be accompanied by symptoms such as diarrhea, fever, malaise, and myalgias (see PRECAUTIONS). Vomiting with abdominal pain may occur rarely with a hypersensitivity pancreatitis. Hepatotoxicity manifest by elevation of serum alkaline phosphatase, bilirubin, and/or serum transaminases is known to occur following azathioprine use, primarily in allograft recipients. Hepatotoxicity has been uncommon (less than 1%) in rheumatoid arthritis patients. Hepatotoxicity following transplantation most often occurs within 6 months of transplantation and is generally reversible after interruption of Azasan. A rare, but life-threatening hepatic veno-occlusive disease associated with chronic administration of azathioprine has been described in transplant patients and in one patient receiving Azasan for panuveitis.21, 22, 23 Periodic measurement of serum transaminases, alkaline phosphatase, and bilirubin is indicated for early detection of hepatotoxicity. If hepatic veno-occlusive disease is clinically suspected, Azasan should be permanently withdrawn.



Others: Additional side effects of low frequency have been reported. These include skin rashes, alopecia, fever, arthralgias, diarrhea, steatorrhea, negative nitrogen balance, reversible interstitial pneumonitis, hepatosplenic T-cell lymphoma (see Warnings – Malignancy), and Sweet's Syndrome (acute febrile neutrophilic dermatosis).



OVERDOSAGE:


The oral LD50s for single doses of Azasan in mice and rats are 2500 mg/kg and 400 mg/kg, respectively. Very large doses of this antimetabolite may lead to marrow hypoplasia, bleeding, infection, and death. About 30% of Azasan is bound to serum proteins, but approximately 45% is removed during an 8-hour hemodialysis.24 A single case has been reported of a renal transplant patient who ingested a single dose of 7500 mg azathioprine. The immediate toxic reactions were nausea, vomiting, and diarrhea, followed by mild leukopenia and mild abnormalities in liver function. The white blood cell count, SGOT, and bilirubin returned to normal 6 days after the overdose.



DOSAGE AND ADMINISTRATION:


TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING Azasan. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from Azasan if conventional doses are given. Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azasan should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.



Renal Homotransplantation: The dose of Azasan required to prevent rejection and minimize toxicity will vary with individual patients; this necessitates careful management. The initial dose is usually 3 to 5 mg/kg daily, beginning at the time of transplant. Azasan is usually given as a single daily dose on the day of, and in a minority of cases 1 to 3 days before, transplantation. Dose reduction to maintenance levels of 1 to 3 mg/kg daily is usually possible. The dose of Azasan should not be increased to toxic levels because of threatened rejection. Discontinuation may be necessary for severe hematologic or other toxicity, even if rejection of the homograft may be a consequence of drug withdrawal.



Rheumatoid Arthritis: Azasan is usually given on a daily basis. The initial dose should be approximately 1.0 mg/kg (50 to 100 mg) given as a single dose or on a twice-daily schedule. The dose may be increased, beginning at 6 to 8 weeks and thereafter by steps at 4-week intervals, if there are no serious toxicities and if initial response is unsatisfactory. Dose increments should be 0.5 mg/kg daily, up to a maximum dose of 2.5 mg/kg per day. Therapeutic response occurs after several weeks of treatment, usually 6 to 8; an adequate trial should be a minimum of 12 weeks. Patients not improved after 12 weeks can be considered refractory. Azasan may be continued long-term in patients with clinical response, but patients should be monitored carefully, and gradual dosage reduction should be attempted to reduce risk of toxicities.


Maintenance therapy should be at the lowest effective dose, and the dose given can be lowered decrementally with changes of 0.5 mg/kg or approximately 25 mg daily every 4 weeks while other therapy is kept constant. The optimum duration of maintenance Azasan has not been determined. Azasan can be discontinued abruptly, but delayed effects are possible.



Use in Renal Dysfunction: Relatively oliguric patients, especially those with tubular necrosis in the immediate post-cadaveric transplant period, may have delayed clearance of Azasan or its metabolites, may be particularly sensitive to this drug, and are usually given lower doses.


Procedures for proper handling and disposal of this immunosuppressive antimetabolite drug should be considered. Several guidelines on this subject have been published.25-31 There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.



HOW SUPPLIED:


Azasan Tablets, USP are available in:


75 mg, triangle-shaped, yellow, scored tablets,


        100 count bottles (NDC 65649-231-41)


        15 count samples (NDC 65649-231-51)


100 mg, diamond-shaped, yellow, scored tablets,


        100 count bottles (NDC 65649-241-41)


        15 count samples (NDC  65649-241-51)


Rx only.


Store at 20º to 25º C (68º to 77º F) [See USP Controlled Room Temperature]


Store in a dry place and protect from light.


Dispense in a tight, light-resistant container as defined in the USP.



REFERENCES:


  1. Lennard L. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992;43:329-339.

  2. Weinshilboum R. Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos. 2001;29:601-605.

  3. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus -- implications for clinical pharmacogenomics. Pharmacogenomics. 2002;3:89-98.

  4. Anstey A, Lennard L, Mayou SC, et al. Pancytopenia related to azathioprine – an enzyme deficiency caused by a common genetic polymorphism: a review. JR Soc Med. 1992; 85:752-756.

  5. Stolk JN, Beorbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998; 41:1858-1866.

  6. Data on file, Prometheus Laboratories Inc.

  7. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997; 126:608-614.

  8. Black AJ, McLeod HL, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998; 129:716-718.

  9. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology. 2004; 43:13-18.

  10. Clark JM. The mutagenicity of azathioprine in mice, Drosophila melanogaster, and Neurospora crassa. Mutat Res. 1975; 28:87-99.

  11. Data on file, Prometheus Laboratories Inc.

  12. Tagatz GE, Simmons RL. Pregnancy after renal transplantation. Ann Intern Med. 1975; 82:113-114. Editorial Notes.

  13. Cote' CJ, Meuwissen HJ, Pickering RJ. Effects on the neonate of prednisone and azathioprine administered to the mother during pregnancy. J Pediatr. 1974; 85:324-328.

  14. DeWitte DB, Buick MK, Cyran SE, et al. Neonatal pancytopenia and severe combined immunodeficiency associated with antenatal administration of azathioprine and prednisone. J Pediatr. 1984; 105:625-628.

  15. Williamson RA, Karp LE. Azathioprine teratogenicity: review of the literature and case report. Obstet Gynecol. 1981; 58:247-250.

  16. Tallent MB, Simmons RL, Najarian JS. Birth defects in child of male recipient of kidney transplant. JAMA. 1970; 211: 1854-1855.

  17. Data on file, Prometheus Laboratories Inc.

  18. Saarikoski S, Seppälä M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973; 115:1100-1106.

  19. Coulam CB, Moyer TP, Jiang NS, et al. Breast-feeding after renal transplantation. Transplant Proc. 1982; 14: 605-609.

  20. Schutz E, Gummert J, Mohr F, Oellerich M. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant patients. Lancet. 1993; 341:436.

  21. Read AE, Wiesner RH, LaBrecque DR, et al. Hepatic veno-occlusive disease associated with renal transplantation and azathioprine therapy. Ann Intern Med. 1986; 104:651-655.

  22. Katzka DA, Saul SH, Jorkasky D, et al. Azathioprine and hepatic veno-occlusive disease in renal transplant patients. Gastroenterology. 1986; 90:446-454.

  23. Weitz H, Gokel JM, Loeshke K, et al. Veno-occlusive disease of the liver in patients receiving immunosuppressive therapy. Virchows Arch A Pathol Anat Histol. 1982; 395:245-256.

  24. Schusziarra V, Ziekursch V, Schlamp R, et al. Pharmacokinetics of azathioprine under haemodialysis. Int J Clin Pharmacol Biopharm. 1976; 14:298-302.

  25. Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety; Clinical Center Pharmacy Department and Cancer Nursing Services, National Institute of Health; 1992. US Dept of Health and Human Services. Public Health Service Publication NIH 92-2621.

  26. AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. JAMA. 1985; 253:1590-1592.

  27. National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.

  28. Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. Med J Aust. 1983; 1:426-428.

  29. Jones RB, Frank R, Mass T. Safe handling of chemotherapeutic agents: a report from The Mount Sinai Medical Center. CA Cancer J for Clinicians. 1983; 33:258-263.

  30. American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am J Hosp Pharm. 1990; 47:1033-1049.

  31. Yodaiken RE, Bennett D. OSHA Work-Practice guidelines for personnel dealing with cytotoxic (antineoplastic) drugs. Am J Hosp Pharm, 1996; 43:1193-1204.

Azasan® is a registered trademark of AAI Properties Inc.


© 2003 aaiPharma LLC


Manufactured by:


AAIPharma Services Corp. 


Wilmington, NC 28405


Manufactured for:



Salix Pharmaceuticals, Inc.


Raleigh, NC 27615


VENART 206-0 AUG 2011



PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Azasan 75 mg Tablets


100 Tablets


NDC 65649-231-41


(azathioprine)


75 mg


Rx Only


Manufactured by:


AAIPharma Inc.


Wilmington, NC 28405


Rev. Oct 2011




PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - Azasan 100 mg Tablets


100 Tablets


NDC 65649-241-41


(azathioprine)


100 mg


Rx Only


Manufactured by:


AAIPharma Inc.


Wilmington, NC 28405


Rev. Oct 2011










Azasan 
azathioprine  tablet










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)65649-241
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AZATHIOPRINE (AZATHIOPRINE)AZATHIOPRINE100 mg














Inactive Ingredients
Ingredient NameStrength
LACTOSE MONOHYDRATE 
STARCH, CORN 
POVIDONE 
MAGNESIUM STEARATE 
STEARIC ACID 


















Product Characteristics
ColorYELLOW (YELLOW)Score2 pieces
ShapeDIAMOND (DIAMOND)Size14mm
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
165649-241-41100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07525204/01/2003







Azasan 
azathioprine  tablet










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)65649-231
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
AZATHIOPRINE (AZATHIOPRINE)AZATHIOPRINE75 mg














Inactive Ingredients
Ingredient NameStrength
LACTOSE MONOHYDRATE 
STARCH, CORN 
POVIDONE 
MAGNESIUM STEARATE 
STEARIC ACID 


















Product Characteristics
ColorYELLOW (YELLOW)Score2 pieces
ShapeTRIANGLE (TRIANGLE)Size14mm
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
165649-231-41100 TABLET In 1 BOTTLENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA07525204/01/2003


Labeler - Salix Pharmaceuticals, Inc. (793108036)
Revised: 12/2011Salix Pharmaceuticals, Inc.



Saturday, 3 March 2012

Calcichew D3 Chewable Tablets





1. Name Of The Medicinal Product



Calcichew-D3 Chewable Tablets


2. Qualitative And Quantitative Composition
















Per tablet:




Calcium carbonate




1250mg




 




(equivalent to 500mg of elemental calcium)




 




 




Colecalciferol




200iu




 




(equivalent to 5 micrograms vitamin D3)




 



Contains sorbitol, 390mg; isomalt, 62mg; aspartame, 1mg; sucrose 0.76mg and soya bean oil, hydrogenated, 0.15mg. For a full list of excipients see section 6.1.



3. Pharmaceutical Form



Chewable tablet.



Round, white, uncoated and convex tablets. May have small specks.



4. Clinical Particulars



4.1 Therapeutic Indications



Calcichew-D3 Chewable Tablets should be used only as a therapeutic and not as a food supplement when the diet is deficient or when normal requirement of both components is increased.



Calcichew-D3 Chewable Tablets may be used as an adjunct to specific therapy for osteoporosis or as a therapeutic supplement in established osteomalacia, pregnant patients at high risk of needing such a therapeutic supplementation or malnutrition when dietary intake is less than that required.



4.2 Posology And Method Of Administration



Oral.



Adjunctive therapy in osteoporosis:



One chewable tablet 2-3 times per day



Calcium and vitamin D deficiency:








Adults




One chewable tablet 2-3 times per day.




Children




One chewable tablet 1-2 times per day.



The tablet may be chewed or sucked.



Dosage in hepatic impairment:



No dose adjustment is required.



Dosage in renal impairment:



Calcichew-D3 chewable tablets should not be used in patients with severe renal impairment.



4.3 Contraindications



• Diseases and/or conditions resulting in hypercalcaemia and/or hypercalciuria



• Nephrolithiasis



• Hypervitaminosis D



• Hypersensitivity to soya or peanut



• Hypersensitivity to the active substances or to any of the excipients



4.4 Special Warnings And Precautions For Use



During long-term treatment, serum calcium levels should be followed and renal function should be monitored through measurement of serum creatinine. Monitoring is especially important in elderly patients on concomitant treatment with cardiac glycosides or diuretics (see section 4.5) and in patients with a high tendency to calculus formation. In case of hypercalcaemia or signs of impaired renal function, the dose should be reduced or the treatment discontinued.



Vitamin D should be used with caution in patients with impairment of renal function and the effect on calcium and phosphate levels should be monitored. The risk of soft tissue calcification should be taken into account. In patients with severe renal insufficiency, vitamin D in the form of colecalciferol is not metabolised normally and other forms of vitamin D should be used (see section 4.3, contraindications).



Calcichew-D3 chewable tablets should be prescribed with caution to patients suffering from sarcoidosis because of the risk of increased metabolism of vitamin D to its active form. These patients should be monitored with regard to the calcium content in serum and urine.



Calcichew-D3 Chewable Tablets should be used with caution in immobilised patients with osteoporosis due to the increased risk of hypercalcaemia.



The content of colecalciferol (200 IU) in Calcichew-D3 Chewable Tablets should be considered when prescribing other medicinal products containing vitamin D or nutrients (such as milk). Additional doses of calcium or vitamin D increase the risk of hypercalcaemia with subsequent kidney function impairment and milk-alkali syndrome; therefore they should be taken under close medical supervision. In such cases it is necessary to monitor serum calcium levels and urinary calcium excretion frequently.



Calcichew-D3 Chewable Tablets contain aspartame (a source of phenylalanine) which may be harmful for people with phenylketonuria.



Calcichew-D3 Chewable Tablets contain sorbitol (E420), isomalt and sucrose. Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Thiazide diuretics reduce the urinary excretion of calcium. Due to increased risk of hypercalcaemia, serum calcium should be regularly monitored during concomitant use of thiazide diuretics.



Systemic corticosteroids reduce calcium absorption. During concomitant use, it may be necessary to increase the dose of Calcichew-D3 Chewable Tablets.



Simultaneous treatment with ion exchange resins such as cholestyramine or laxatives such as paraffin oil may reduce the gastrointestinal absorption of vitamin D.



Calcium carbonate may interfere with the absorption of concomitantly administered tetracycline preparations. For this reason, tetracycline preparations should be administered at least two hours before, or four to six hours after, oral intake of calcium.



Hypercalcaemia may increase the toxicity of cardiac glycosides during treatment with calcium and vitamin D. Patients should be monitored with regard to electrocardiogram (ECG) and serum calcium levels.



If a bisphosphonate or sodium fluoride is used concomitantly, this preparation should be administered at least three hours before the intake of Calcichew-D3 Chewable Tablets since gastrointestinal absorption may be reduced.



The efficacy of levothyroxine can be reduced by the concurrent use of calcium, due to decreased levothyroxine absorption. Administration of calcium and levothyroxine should be separated by at least four hours.



The absorption of quinolone antibiotics may be impaired if administered concomitantly with calcium. Quinolone antibiotics should be taken two hours before or after intake of calcium.



Oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole cereals) may inhibit calcium absorption through formation of insoluble calcium salts. The patient should not take calcium products within two hours of eating foods high in oxalic acid and phytic acid.



4.6 Pregnancy And Lactation



Pregnancy



During pregnancy the daily intake should not exceed 1500 mg calcium and 600 IU vitamin D). Studies in animals have shown reproductive toxicity with high doses of vitamin D. In pregnant women, overdoses of calcium and vitamin D should be avoided as permanent hypercalcaemia has been related to adverse effects on the developing foetus. There are no indications that vitamin D at therapeutic doses is teratogenic in humans. Calcichew-D3 Chewable Tablets can be used during pregnancy, in case of a calcium and vitamin D deficiency.



Lactation



Calcichew-D3 Chewable Tablets can be used during breast-feeding. Calcium and vitamin D3 pass into breast milk. This should be considered when giving additional vitamin D to the child.



4.7 Effects On Ability To Drive And Use Machines



There are no data about the effect of this product on driving capacity. An effect is, however, unlikely.



4.8 Undesirable Effects



Adverse reactions are listed below, by system organ class and frequency. Frequencies are defined as: uncommon (



Metabolism and nutrition disorders



Uncommon: Hypercalcaemia and hypercalciuria.



Very rare: Seen usually only in overdose, see 4.9: Milk-alkali syndrome



Gastrointestinal disorders



Rare: Constipation, dyspepsia, flatulence, nausea, abdominal pain and diarrhoea.



Skin and subcutaneous disorders



Rare: Pruritus, rash and urticaria.



4.9 Overdose



Overdose can lead to hypervitaminosis D and hypercalcaemia. Symptoms of hypercalcaemia may include anorexia, thirst, nausea, vomiting, constipation, abdominal pain, muscle weakness, fatigue, mental disturbances, polydipsia, polyuria, bone pain, nephrocalcinosis, nephrolithiasis and in severe cases, cardiac arrhythmias. Extreme hypercalcaemia may result in coma and death. Persistently high calcium levels may lead to irreversible renal damage and soft tissue calcification.



Milk-alkali syndrome (frequent urge to urinate; continuing headache; continuing loss of appetite; nausea or vomiting; unusual tiredness or weakness; hypercalcaemia, alkalosis and renal impairment). The milk-alkali syndrome of hypercalcaemia, alkalosis and renal impairment still occur in patients who ingest large amounts of calcium and absorbable alkali; it is not uncommon as a cause of hypercalcaemia requiring hospitalisation. The syndrome has also been reported in a patient taking recommended doses of antacids containing calcium carbonate for chronic epigastric discomfort, and in a pregnant woman taking high, but not grossly excessive, doses of calcium (about 3 g of elemental calcium daily). Metastatic calcification can develop.



Treatment of hypercalcaemia: The treatment with calcium and vitamin D must be discontinued. Treatment with thiazide diuretics, lithium, vitamin A and cardiac glycosides must also be discontinued. Teatment is rehydration, and, according to severity of hypercalcaemia, isolated or combined treatment with loop diuretics, bisphosphonates, calcitonin and corticosteroids should be considered. Serum electrolytes, renal function and diuresis must be monitored. In severe cases, ECG and CVP should be followed.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Mineral supplements



ATC code: A12AX



Vitamin D increases the intestinal absorption of calcium.



Administration of calcium and vitamin D3 counteracts the increase of parathyroid hormone (PTH) which is caused by calcium deficiency and which causes increased bone resorption.



A clinical study of institutionalised patients suffering from vitamin D deficiency indicated that a daily intake of two tablets of calcium 500mg/vitamin D 400 IU for six months normalised the value of the 25-hydroxylated metabolite of vitamin D3 and reduced secondary hyperparathyroidism and alkaline phosphatases.



5.2 Pharmacokinetic Properties



Calcium



Absorption: The amount of calcium absorbed through the gastrointestinal tract is approximately 30% of the swallowed dose.



Distribution and metabolism: 99% of the calcium in the body is concentrated in the hard structure of bones and teeth. The remaining 1% is present in the intra- and extracellular fluids. About 50% of the total blood-calcium content is in the physiologically active ionised form with approximately 10% being complexed to citrate, phosphate or other anions, the remaining 40% being bound to proteins, principally albumin.



Elimination: Calcium is eliminated through faeces, urine and sweat. Renal excretion depends on glomerular filtration and calcium tubular reabsorption.



Vitamin D



Absorption: Vitamin D is easily absorbed in the small intestine.



Distribution and metabolism: Colecalciferol and its metabolites circulate in the blood bound to a specific globulin. Colecalciferol is converted in the liver by hydroxylation to the active form 25-hydroxycolecalciferol. It is then further converted in the kidneys to 1,25



Elimination: Vitamin D is excreted in faeces and urine.



5.3 Preclinical Safety Data



At doses far higher than the human therapeutic range teratogenicity has been observed in animal studies. There is no further information of relevance to the safety assessment in addition to what is stated in other parts of the SmPC.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sorbitol (E420)



Povidone



Isomalt (E953)



Flavour (orange)



Magnesium stearate



Aspartame (E951)



Mono, di-fatty acid glycerides



Sucrose



Gelatin



Soya-bean oil, hydrogenated



Tocopherol



Maize starch



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



3 years.



6.4 Special Precautions For Storage



Do not store above 30°C. Keep the container tightly closed to protect from moisture.



6.5 Nature And Contents Of Container



White HD Polyethylene containers with a primary tamper-evident seal and secondary re-sealable closure containing 60 and 100 tablets.



Not all pack sizes may be marketed.



6.6 Special Precautions For Disposal And Other Handling



No special requirements.



7. Marketing Authorisation Holder



Shire Pharmaceuticals Ltd.



Hampshire International Business Park



Chineham



Basingstoke



Hampshire RG24 8EP



United Kingdom



8. Marketing Authorisation Number(S)



PL 08557/0021



9. Date Of First Authorisation/Renewal Of The Authorisation



26 November 1991



10. Date Of Revision Of The Text



09-Jun-2010